After Enhertu pioneered the HER2-low category in breast cancer treatment, AstraZeneca and Daiichi Sankyo are now hopeful that the antibody-drug conjugate can reach tumors with an even lower expression ...
AstraZeneca and Daiichi Sankyo have officially escalated the competition in HER2-positive breast cancer treatment. Thursday, AZ and Daiichi said the FDA has approved their rising star Enhertu for ...
Devon mum with incurable breast cancer pleads for life-extending treatment to give her more time with daughter - The ...
Ground-breaking Phase III head-to-head DESTINY-Breast03 results featured at ESMO Presidential Symposium support ENHERTU as the potential new standard of care in previously treated patients ...
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca's Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six ...
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. The Food and Drug Administration on Monday expanded ...
Based on DESTINY-Breast06 Phase III trial results which showed ENHERTU demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year Approval brings ...
The FDA will speed up their review of Enhertu for HR-positive, HER2-low/ultralow advanced breast cancer that cannot be removed via surgery. The Food and Drug Administration (FDA) granted a ...
The approval allows certain patients to receive Enhertu earlier in their treatment course. Credit: FatCamera via Getty Images. · Pharmaceutical Technology · FatCamera via Getty Images. The above ...
The cost of Enhertu (fam-trastuzumab deruxtecan-nxki) can vary based on several factors, including your insurance coverage. Coupons and drug savings programs can also lower the price you’ll pay for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results